-
Je něco špatně v tomto záznamu ?
Effect of ivabradine, captopril and melatonin on the behaviour of rats in L-nitro-arginine methyl ester-induced hypertension
S. Aziriova, K. Repova, K. Krajcirovicova, T. Baka, S. Zorad, V. Mojto, P. Slavkovsky, J. Hodosy, M. Adamcova, L. Paulis, F. Simko,
Jazyk angličtina Země Polsko
Typ dokumentu časopisecké články
Odkazy
PubMed
28195070
Knihovny.cz E-zdroje
- MeSH
- antihypertenziva farmakologie MeSH
- benzazepiny farmakologie MeSH
- chování zvířat účinky léků MeSH
- hypertenze farmakoterapie metabolismus MeSH
- inhibitory ACE farmakologie MeSH
- kaptopril farmakologie MeSH
- krevní tlak účinky léků MeSH
- krysa rodu rattus MeSH
- lokomoce účinky léků MeSH
- melatonin farmakologie MeSH
- NG-nitroargininmethylester metabolismus MeSH
- oxid dusnatý metabolismus MeSH
- potkani Wistar MeSH
- srdeční frekvence účinky léků MeSH
- synthasa oxidu dusnatého metabolismus MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Cardiovascular diseases including hypertension are often associated with behavioural alterations. The aim of this study was to show, whether ivabradine, the blocker of If-channel in sinoatrial node, is able to modify the behaviour of rats in L-nitro-arginine methyl ester (L-NAME)-induced hypertension and to compare the effect of ivabradine with captopril and melatonin. 12-week-old male Wistar rats were divided into the following groups: controls, ivabradine (10 mg/kg/24 h), L-NAME (40 mg/kg/24 h), L-NAME + ivabradine, L-NAME + captopril (100 mg/kg/24 h), L-NAME + melatonin (10 mg/kg/24 h). Systolic blood pressure (SBP) and heart rate (HR) were measured by tail-cuff method once a week. The behaviour of rats was investigated during 23-hours in the phenotyper after four weeks of the treatment. Chronic administration of L-NAME induced hypertension without a change in HR. All tested substances partly prevented the increase of SBP, while ivabradine and melatonin also reduced HR. Ivabradine, captopril and melatonin reduced daily food intake, slightly decreased daily water intake and attenuated body weight gain. In L-NAME group, locomotor activity was enhanced by ivabradine, whereas exploratory behaviour was increased by melatonin and captopril. In conclusion, ivabradine, besides its potentially protective hemodynamic actions, does not seem to exert any disturbing effects on behaviour in L-NAME-induced hypertension in rats, while some of its effects were similar to captopril or melatonin. It is suggested that ivabradine used in cardiovascular indications is harmless regarding the effect on behaviour.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023293
- 003
- CZ-PrNML
- 005
- 20231121090556.0
- 007
- ta
- 008
- 170720s2016 pl f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)28195070
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a pl
- 100 1_
- $a Aziriova, S $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic. $7 gn_A_00010713
- 245 10
- $a Effect of ivabradine, captopril and melatonin on the behaviour of rats in L-nitro-arginine methyl ester-induced hypertension / $c S. Aziriova, K. Repova, K. Krajcirovicova, T. Baka, S. Zorad, V. Mojto, P. Slavkovsky, J. Hodosy, M. Adamcova, L. Paulis, F. Simko,
- 520 9_
- $a Cardiovascular diseases including hypertension are often associated with behavioural alterations. The aim of this study was to show, whether ivabradine, the blocker of If-channel in sinoatrial node, is able to modify the behaviour of rats in L-nitro-arginine methyl ester (L-NAME)-induced hypertension and to compare the effect of ivabradine with captopril and melatonin. 12-week-old male Wistar rats were divided into the following groups: controls, ivabradine (10 mg/kg/24 h), L-NAME (40 mg/kg/24 h), L-NAME + ivabradine, L-NAME + captopril (100 mg/kg/24 h), L-NAME + melatonin (10 mg/kg/24 h). Systolic blood pressure (SBP) and heart rate (HR) were measured by tail-cuff method once a week. The behaviour of rats was investigated during 23-hours in the phenotyper after four weeks of the treatment. Chronic administration of L-NAME induced hypertension without a change in HR. All tested substances partly prevented the increase of SBP, while ivabradine and melatonin also reduced HR. Ivabradine, captopril and melatonin reduced daily food intake, slightly decreased daily water intake and attenuated body weight gain. In L-NAME group, locomotor activity was enhanced by ivabradine, whereas exploratory behaviour was increased by melatonin and captopril. In conclusion, ivabradine, besides its potentially protective hemodynamic actions, does not seem to exert any disturbing effects on behaviour in L-NAME-induced hypertension in rats, while some of its effects were similar to captopril or melatonin. It is suggested that ivabradine used in cardiovascular indications is harmless regarding the effect on behaviour.
- 650 _2
- $a inhibitory ACE $x farmakologie $7 D000806
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antihypertenziva $x farmakologie $7 D000959
- 650 _2
- $a chování zvířat $x účinky léků $7 D001522
- 650 _2
- $a benzazepiny $x farmakologie $7 D001552
- 650 _2
- $a krevní tlak $x účinky léků $7 D001794
- 650 _2
- $a kaptopril $x farmakologie $7 D002216
- 650 _2
- $a srdeční frekvence $x účinky léků $7 D006339
- 650 _2
- $a hypertenze $x farmakoterapie $x metabolismus $7 D006973
- 650 _2
- $a lokomoce $x účinky léků $7 D008124
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a melatonin $x farmakologie $7 D008550
- 650 _2
- $a NG-nitroargininmethylester $x metabolismus $7 D019331
- 650 _2
- $a oxid dusnatý $x metabolismus $7 D009569
- 650 _2
- $a synthasa oxidu dusnatého $x metabolismus $7 D019001
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Repova, K $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
- 700 1_
- $a Krajcirovicova, K $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
- 700 1_
- $a Baka, T $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
- 700 1_
- $a Zorad, Štefan, $d 1956- $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovak Republic. $7 xx0310348
- 700 1_
- $a Mojto, V $u 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
- 700 1_
- $a Slavkovsky, P $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
- 700 1_
- $a Hodosy, J $u Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
- 700 1_
- $a Adamcova, M $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic. $7 gn_A_00001173
- 700 1_
- $a Paulis, L $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic. Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, Slovak Republic.
- 700 1_
- $a Simko, F $u Department of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic. fedor.simko@fmed.uniba.sk. Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovak Republic. 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.
- 773 0_
- $w MED00002908 $t Journal of physiology and pharmacology $x 1899-1505 $g Roč. 67, č. 6 (2016), s. 895-902
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28195070 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20231121090553 $b ABA008
- 999 __
- $a ok $b bmc $g 1238974 $s 984206
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 67 $c 6 $d 895-902 $i 1899-1505 $m Journal of physiology and pharmacology $n J Physiol Pharmacol $x MED00002908
- LZP __
- $a Pubmed-20170720